• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.



    BALTIMORE (April 4, 2012) – The Department of Health and Mental Hygiene (DHMH) today issued an alert regarding the use of an unapproved medicine called Baczol, which contains an antibiotic that would ordinarily require a prescription and is ineffective against some of the conditions for which it is commonly purchased. This unapproved medicine, which is produced outside the United States, has been found in a number of convenience stores that serve Latino communities and is marketed specifically for pediatric populations under the names Baczol, Pediatric Baczol, or Baczol Antigripal. The U.S. Food and Drug Administration has issued an import alert for this medication (Import Alert # 66-41, 2/7/2011).
    Concern about this medication was raised when a clinician at the Bayview Medical Center in Baltimore heard from several Hispanic families that they were purchasing from local Latino convenient stores an over the counter “cold medication” and giving it to their children. The clinician became concerned about the medication and recognized that it represented a potential hazard to young children. She contacted the Baltimore City Health Department, which investigated local Latino convenience stores and found Baczol for sale in three of them. A further investigation revealed that the product is available for sale in other locations in Maryland.
    “Unapproved medications represent a serious danger to patients,” said Dr. Joshua M. Sharfstein, Secretary of DHMH. “Prompt reporting by this very alert clinician has potentially saved lives.”
    Consumers who are already using this product should consult their health care provider. The Department recommends that health care providers ask patients whether they have used or are using this product. If so, providers are urged to recommend that their patients discontinue use of the product. In addition, providers or others who are aware that the product is for sale are urged to contact their local health department.
    'We hope providers statewide will take care to warn parents about the potential dangers associated with unapproved, unregulated medications like this one,' said Dr. Laura Herrera, Chief Medical Officer at DHMH.